BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months

February 2, 2024

https://www.globenewswire.com/news-release/2024/02/02/2822760/0/en/BridgeBio-Pharma-Shares-Positive-Results-of-Single-Arm-Phase-3-Study-of-Acoramidis-in-Japanese-Patients-with-Transthyretin-Amyloid-Cardiomyopathy-ATTR-CM-Including-No-Mortality-Rep.html

– Phase 3 open-label, single-arm study conducted in Japan by BridgeBio licensing partner Alexion, AstraZeneca Rare Disease showed consistency with global ATTRibute-CM Phase III trial

Read more at globenewswire.com

Related news for (BBIO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.